NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
University of California, San Diego
Mayo Clinic
National Cancer Institute (NCI)
Boehringer Ingelheim
CHU de Reims
Revolution Medicines, Inc.
Akamis Bio
UniversitÀtsklinikum Hamburg-Eppendorf
Adaptimmune
Novartis
UNC Lineberger Comprehensive Cancer Center
CRISPR Therapeutics
Jemincare
Sanofi
Leiden University Medical Center
University Health Network, Toronto
University of California, San Diego
Baptist Health South Florida
Verrica Pharmaceuticals Inc.
Pfizer
Hoffmann-La Roche
National Cancer Centre, Singapore
Akamis Bio
Akamis Bio
Laval University
HiberCell, Inc.
Sichuan University
Intensity Therapeutics, Inc.
Sirtex Medical
Vaccinex Inc.
University of California, San Diego
BeiGene
Columbia University
Changsha Medical University
Imunon
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Federation Francophone de Cancerologie Digestive
Keystone Nano, Inc
Advaxis, Inc.
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd.
Pfizer
Steba Biotech S.A.
UNICANCER
Celgene
University of Chicago
MedImmune LLC